Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Innoviva Aims For Antibiotic Success With La Jolla, Entasis Acquisitions

$149m La Jolla Purchase Expands Hospital Presence

Jul 11 2022

• By Mandy Jackson

Merging; two merchants push one red square and three white squares together — Innoviva hopes to add a future Entasis product into La Jolla's commercial portfolio • Source: Shutterstock

Related Content

La Jolla’s Giapreza: Emergency Use Requests Sped US FDA Approval For Septic Shock

May 18 2018

Deal Watch: Merck Gets Rights To Yumanity’s Preclinical ALS, FTLD Candidates

Jun 24 2020

Theravance Seeks A Way Back From Second Ampreloxetine Disappointment

Apr 14 2022

Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m

May 26 2022

Entasis Anticipates First FDA Approval Of Pathogen-Specific Antibacterial

Oct 21 2021

Related Companies

Innoviva, Inc.

La Jolla Pharmaceutical Company

Entasis Therapeutics Holdings Inc.

Tetraphase Pharmaceuticals, Inc.

Theravance Biopharma Inc.

Armata Pharmaceuticals, Inc.

Additional Topics

Deals M & A Business Strategies Strategy Companies Commercial Infectious Diseases BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window